GRAL - GRAIL Inc. Stock Analysis

Latest News

PRNEWSWIRE · OCT 5, 2026

GRAIL to Present New Data From NHS-Galleri and PATHFINDER 2 at EDCC and ESMO Congress 2026

GRAIL to Present Six Abstracts at the Early Detection of Cancer Conference (EDCC) Spanning Clinical Performance, Health Equity, and Real-World Implementation of Multi-Cancer Early Detection GRAIL to Present Two Abstracts at the European Society for Medical Oncology (ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World Evidence SUNNYVALE, Calif., Oct. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the Early Detection of Cancer Conference (EDCC) in Edinburgh, the United Kingdom, taking place Oct. 6-8, 2026, and at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain taking place Oct. 23-27, 2026.

READ ARTICLE

EARLIER COVERAGE

THE MOTLEY FOOL · OCT 4, 2026

Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?

Adoption by insurers and FDA approval are critical for future performance. Profitability is not expected until 2032/2033, but revenue growth could be strong if adoption accelerates.

READ ARTICLE

DEFENSE WORLD · OCT 2, 2026

GRAIL (NASDAQ:GRAL) Shares Climb 5.5% – Time to Buy?

Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) rose 5.5% during mid-day trading on Wednesday. The stock traded as high as $141.97 and last traded at $144.0280. Approximately 113,792 shares were traded during trading, a decline of 88% from the average daily volume of 962,223 shares. The stock had previously closed at $136.57. Analyst

READ ARTICLE

DEFENSE WORLD · OCT 1, 2026

GRAIL (NASDAQ:GRAL) Hits New 12-Month High – Should You Buy?

Shares of GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) hit a new 52-week high on Thursday. The company traded as high as $151.46 and last traded at $140.12, with a volume of 1920136 shares trading hands. The stock had previously closed at $136.57. Wall Street Analysts Forecast Growth Several equities research analysts recently issued reports

READ ARTICLE

THE MOTLEY FOOL · SEP 30, 2026

3 Reasons to Buy Grail (GRAL) Hand Over Fist in October

Grail's stock recently hit its all-time high. If the FDA approves Galleri, it still looks reasonably valued.

READ ARTICLE

THE MOTLEY FOOL · SEP 30, 2026

Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run.

The key to the company's future is medical insurers adopting Galleri. The FDA looks likely to grant pre-market approval for Galleri following this week's vote.

READ ARTICLE